Is Privacy Overrated in Pharmacovigilance? Data vs Patient Confidentiality
Explore the balance between patient privacy and data access in pharmacovigilance and how it impacts AI, signal detection, and drug safety outcomes.
AI is transformative, but it is also hungry. To deliver faster signal detection, earlier AE identification, and safer medicines, it requires vast amounts of raw data. This raises an uncomfortable dilemma: should we sacrifice privacy protection for greater data access?
"I see AI as born out of the surveillance business model… AI is basically a way of deriving more power, more revenue, more market reach that needs more and more data."
— Meredith Whittaker, President of Signal Foundation
The Case for Broader Data Access
There are arguments for relaxing privacy constraints. Many serious adverse reactions are rare, appearing only after millions of patients are exposed. Larger, cross-border datasets increase the chance of detecting these signals earlier. Broader data also improves representativeness, ensuring risks are identified across diverse ethnicities and age groups rather than well-documented majorities alone.
In public health emergencies, can we afford to be constrained by privacy rules when rapid data pooling could accelerate benefit–risk assessments? Across industries, greater data volume and quality drive better prediction, innovation, and efficiency. Richer datasets reduce duplication, automate case handling, and accelerate AI improvement. Restrictive privacy rules may not just slow innovation, but delay life-saving insights.
Why Trust Still Matters
However, what we must remember is that pharmacovigilance depends on trust. Patients and healthcare professionals voluntarily share sensitive health information. If individuals fear inadequate protection, reporting behaviours may change.
This may lead to:
- Underreporting
- Incomplete data
- Avoidance of healthcare systems
More data does not necessarily mean better data. Fear reduces quality, and poor-quality data weakens AI outputs.
Ethical and Legal Considerations
Ethical and legal considerations further complicate the issue. Health data reflects personal autonomy and dignity, not merely data assets. Frameworks like GDPR exist because misuse can cause real harms, including discrimination or loss of confidentiality.
Weakening protections exposes organizations to:
- Legal challenges
- Reputational damage
- Erosion of public trust
Centralising vast datasets also increases cybersecurity risk, where a single breach could expose millions of records.
Safety Depends on Privacy
Ultimately, AI performance depends more on governance and data quality than pure scale. Biased or poorly curated data can amplify harm rather than accelerate insight.
The debate is not privacy versus safety. Safety depends on privacy.
Organizations implementing structured systems such as a PV Quality Management System are better positioned to maintain both data integrity and compliance.
The Way Forward
Sustainable pharmacovigilance requires both strong data access and public trust. The future lies in secure systems, advanced anonymisation, and transparent oversight mechanisms.
Optimising data quality while upholding privacy is not a cautious compromise. It is the only viable path forward.
Trust is not a constraint on innovation. It is its foundation.
At PVCON, we support organizations in building pharmacovigilance systems that balance data access, governance, and compliance.
If you want to evaluate whether your systems are aligned with regulatory expectations and patient trust, connect with our team through the contact page or explore our PV consulting services.